Skip to main content
logo
Jeil Pharma Holdings Inc (KRX:002620)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,970.00
-240.00 (-3.33%)
Aug 3, 2026, 3:30 PM KST

Jeil Pharma Holdings Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
13,44114,635-51,159-16,250-74,556-3,482
Depreciation & Amortization
15,05914,94914,09912,55610,9058,983
Loss (Gain) From Sale of Assets
-8.88-12.08-7.97-0.53-23.98-1,930
Asset Writedown & Restructuring Costs
--45,20428,60478,33516,388
Loss (Gain) From Sale of Investments
-5,184-5,175-5,586-2,916-6,271-20,857
Loss (Gain) on Equity Investments
-26,282-24,722-9,855-9,329-5,708-8,452
Stock-Based Compensation
599.05696.531,026578.03472.48163.17
Provision & Write-off of Bad Debts
392558.49-682.67-2,423-308.411,669
Other Operating Activities
34,94928,90026,15113,3092,0146,516
Change in Accounts Receivable
32,12626,816-11,223-14,328-12,72210,835
Change in Inventory
-1,4084,868-3,266-12,1701,3479,341
Change in Accounts Payable
-49,386-50,188-7,721-9,8493,35810,024
Change in Other Net Operating Assets
-2,401-10,9367,5637,803-14,098-15,795
Operating Cash Flow
11,896390.264,542-4,416-17,25613,403
Operating Cash Flow Growth
--91.41%----

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-9,427-8,283-4,340-6,223-15,462-23,688
Sale of Property, Plant & Equipment
58.1412.28.3587.6423.9837,800
Sale (Purchase) of Intangibles
-1,054-1,045-2,523-3,571-5,94891.43
Investment in Securities
-7,158-5,3128,508-3,770169.41-10,506
Other Investing Activities
-0-0620.4351.01106.463,627
Investing Cash Flow
-17,581-14,6282,274-13,425-21,1107,325

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-24,11513,84325,83427,163-
Long-Term Debt Issued
-5,000---12,288
Total Debt Issued
28,53829,11513,84325,83427,16312,288
Short-Term Debt Repaid
--16,500-13,000---42,477
Long-Term Debt Repaid
--938-5,254-4,084-6,377-7,146
Total Debt Repaid
-21,529-17,438-18,254-4,084-6,377-49,623
Net Debt Issued (Repaid)
7,00811,677-4,41121,75020,785-37,335
Issuance of Common Stock
3,191----7,498
Repurchase of Common Stock
-----396.98-810.02
Dividends Paid
-183.17-183.17-1,134-1,134-1,475-1,590
Other Financing Activities
-489.25-280.7219,762-026,00120,000
Financing Cash Flow
9,52711,21314,21720,61644,914-12,238

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-136.57-607.381,749-496.29-369.37-93.19
Net Cash Flow
3,705-3,63122,7822,2796,1798,397

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
2,469-7,893202.38-10,638-32,717-10,284
Free Cash Flow Growth
------
Free Cash Flow Margin
0.39%-1.20%0.03%-1.32%-4.13%-1.35%
Free Cash Flow Per Share
160.72-514.1813.19-692.99-2131.27-669.95
Levered Free Cash Flow
5,2002,34111,675-19,889-20,2307,866
Unlevered Free Cash Flow
9,8617,02517,221-13,219-16,5109,921

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
7,6137,5938,0519,0444,8912,592
Cash Income Tax Paid
11,9119,0933,2892,092-596.655,401
Change in Working Capital
-21,068-29,439-14,647-28,544-22,11514,405